Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FISONS' AEROSOLIZED PENTAMIDINE TREATMENT IND: FDA

Executive Summary

FISONS' AEROSOLIZED PENTAMIDINE TREATMENT IND: FDA has reportedly extended the time that the agency has to consider the application by an additional 30 days in order to review patient report forms submitted on April 19. Under FDA regulations, the agency is supposed to respond to a Treatment IND request in 30 days. Fisons submitted its aerosolized pentamidine Treatment IND on March 30. The company was reportedly notified by FDA on April 28 that the agency needed more time to assess the application. Fisons submitted a full NDA for its aerosolized pentamidine product on April 24, one week before a scheduled meeting of FDA's Anti-Infective Drug Products Advisory Committee. Fisons still hopes to be included on the May 1 advisory committee agenda. However, to date, the committee only plans to consider Lyphomed's aerosolized pentamidine (Pentam) NDA for prophylaxis of the AIDS-related opportunistic infection Pneumocystis carinii pneumonia (PCP). During the open hearing portion of the meeting, Fisons will have an opportunity to present data on its product, Pneumopent. In preparation for the meeting, the company has distributed Pneumopent clinical study results to advisory committee members. FDA Commissioner Young will reportedly be attending the advisory committee meeting.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel